Just because a healthcare AI product gets loudly promoted doesn’t mean its claims are bogus. The salient question is whether or not it performs as well in a clinical setting as it did in a research lab—or in a marketer’s mind. 

“Coronary calcium revealed long ago that atherosclerosis begins well before symptoms. AI-CVD extends that insight by enabling systematic identification of patients who are unaware of their cardiovascular risk using CT scans that already exist,” said Arthur Agatston, MD.

Across industries, more than a third of the time saved by AI gets eaten by overstretched humans who have to clean up the technology’s sloppy work. 

The tech giant is making each model publicly available so that researchers and developers can have access to the updated technology. 

The entrepreneur took to X this week to tout his accomplishment, which was achieved with the help of Anthropic’s Claude AI.

AI-CVD is a quantitative imaging tool that uses computed tomography images to identify and quantify a myriad diseases. 

Previous research has shown that resistance to medical AI may be caused by difficulty in understanding both algorithms and human decision-making in healthcare. 

The FDA wants designers of goods in two health-tech categories to worry more about supplying innovative products than about pleasing the FDA.